IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-50376-z.html
   My bibliography  Save this article

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

Author

Listed:
  • Lindsey R. Baden

    (Brigham and Women’s Hospital)

  • Hana M. El Sahly

    (Baylor College of Medicine)

  • Brandon Essink

    (Meridian Clinical Research Omaha)

  • Dean Follmann

    (National Institute of Allergy and Infectious Disease)

  • Gregory Hachigian

    (Benchmark Research)

  • Cynthia Strout

    (Coastal Carolina Research Center)

  • J. Scott Overcash

    (Velocity Clinical Research)

  • Susanne Doblecki-Lewis

    (University of Miami)

  • Jennifer A. Whitaker

    (Baylor College of Medicine)

  • Evan J. Anderson

    (Emory University School of Medicine)

  • Kathleen Neuzil

    (University of Maryland)

  • Lawrence Corey

    (Fred Hutchinson Cancer Research Center)

  • Frances Priddy

    (Inc.)

  • Joanne E. Tomassini

    (Inc.)

  • Mollie Brown

    (Inc.)

  • Bethany Girard

    (Inc.)

  • Dina Stolman

    (Inc.)

  • Veronica Urdaneta

    (Inc.)

  • Xiaowei Wang

    (Inc.)

  • Weiping Deng

    (Inc.)

  • Honghong Zhou

    (Inc.)

  • Avika Dixit

    (Inc.)

  • Rituparna Das

    (Inc.)

  • Jacqueline M. Miller

    (Inc.)

Abstract

Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A of the phase 3 Coronavirus Efficacy (COVE; NCT04470427) trial in adults (≥18 years) across 99 U.S. sites. The open-label (Parts B and C) primary objectives were evaluation of long-term safety and effectiveness of primary vaccination plus a 50-µg booster dose; immunogenicity was a secondary objective. Of 29,035 open-label participants, 19,609 received boosters (mRNA-1273 [n = 9647]; placebo-mRNA-1273 [n = 9952]; placebo [n = 10] groups). Booster safety was consistent with that reported for primary vaccination. Incidences of COVID-19 and severe COVID-19 were higher during the Omicron BA.1 than Delta variant waves and boosting versus non-boosting was associated with a significant, 47.0% (95% CI : 39.0-53.9%) reduction of Omicron BA.1 incidence (24.6 [23.4 − 25.8] vs 46.4 [40.6 − 52.7]/1000 person-months). In an exploratory Cox regression model adjusted for time-varying covariates, a longer median interval between primary vaccination and boosting (mRNA-1273 [13 months] vs placebo-mRNA-1273 [8 months]) was associated with significantly lower, COVID-19 risk (24.0% [16.0% − 32.0%]) during Omicron BA.1 predominance. Boosting elicited greater immune responses against SARS-CoV-2 than primary vaccination, irrespective of prior SARS-CoV-2 infection. Primary vaccination and boosting with mRNA-1273 demonstrated acceptable safety, effectiveness and immunogenicity against COVID-19, including emergent variants.

Suggested Citation

  • Lindsey R. Baden & Hana M. El Sahly & Brandon Essink & Dean Follmann & Gregory Hachigian & Cynthia Strout & J. Scott Overcash & Susanne Doblecki-Lewis & Jennifer A. Whitaker & Evan J. Anderson & Kathl, 2024. "Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases," Nature Communications, Nature, vol. 15(1), pages 1-13, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50376-z
    DOI: 10.1038/s41467-024-50376-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-50376-z
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-50376-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Julia Stowe & Nick Andrews & Freja Kirsebom & Mary Ramsay & Jamie Lopez Bernal, 2022. "Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    2. Spyros Chalkias & Charles Harper & Keith Vrbicky & Stephen R. Walsh & Brandon Essink & Adam Brosz & Nichole McGhee & Joanne E. Tomassini & Xing Chen & Ying Chang & Andrea Sutherland & David C. Montefi, 2023. "Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19," Nature Communications, Nature, vol. 14(1), pages 1-7, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Denis Mongin & Nils Bürgisser & Gustavo Laurie & Guillaume Schimmel & Diem-Lan Vu & Stephane Cullati & Delphine Sophie Courvoisier, 2023. "Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection," Nature Communications, Nature, vol. 14(1), pages 1-13, December.
    2. Zhuoying Huang & Shuangfei Xu & Jiechen Liu & Linlin Wu & Jing Qiu & Nan Wang & Jia Ren & Zhi Li & Xiang Guo & Fangfang Tao & Jian Chen & Donglei Lu & Yuheng Wang & Juan Li & Xiaodong Sun & Weibing Wa, 2023. "Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: retrospective cohort study," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    3. Hung Fu Tseng & Bradley K. Ackerson & Katia J. Bruxvoort & Lina S. Sy & Julia E. Tubert & Gina S. Lee & Jennifer H. Ku & Ana Florea & Yi Luo & Sijia Qiu & Soon Kyu Choi & Harpreet S. Takhar & Michael , 2023. "Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    4. Lloyd A. C. Chapman & Maite Aubry & Noémie Maset & Timothy W. Russell & Edward S. Knock & John A. Lees & Henri-Pierre Mallet & Van-Mai Cao-Lormeau & Adam J. Kucharski, 2023. "Impact of vaccinations, boosters and lockdowns on COVID-19 waves in French Polynesia," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    5. Freja Cordelia Møller Kirsebom & Nick Andrews & Ruchira Sachdeva & Julia Stowe & Mary Ramsay & Jamie Lopez Bernal, 2022. "Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England," Nature Communications, Nature, vol. 13(1), pages 1-9, December.
    6. Hung Fu Tseng & Bradley K. Ackerson & Lina S. Sy & Julia E. Tubert & Yi Luo & Sijia Qiu & Gina S. Lee & Katia J. Bruxvoort & Jennifer H. Ku & Ana Florea & Harpreet S. Takhar & Radha Bathala & Cindy Ke, 2023. "mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States," Nature Communications, Nature, vol. 14(1), pages 1-11, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-50376-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.